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neurons can live for more than 80 years in the 
human brain; however, in some cases, they 
are also vulnerable and can die as a result 
of various factors. since neurons cannot be 
replaced once they are lost, it is crucial to 
keep them healthy, and, therefore, to under-
stand the mechanisms of their survival and 
death is important. neurons are terminally 
differentiated cells, quiescent in their cell cycle 
activities. if mitotic activity is activated ectopi-
cally, neurons undergo cell death with incom-
plete DnA replication after reentering the cell 
cycle. Thus, cell cycle activation is a cause of 
neuronal cell death, which is associated with 
many neurodegenerative diseases, including 
Alzheimer.1
Cyclin-dependent kinases (Cdks) are key 
players in the promotion of cell cycle progres-
sion in proliferating cells. Cdk5 is the atypical 
member of the Cdk family, and it plays a role in 
many neuronal activities unrelated to the cell 
cycle.2 Although Cdk5 displays kinase activity 
similar to cell cycle Cdks, it has a distinct sub-
cellular localization. Unlike the localization of 
the cell cycle Cdks in the nucleus, the majority 
of Cdk5 activity is associated with membranes 
in the cytoplasm. Membrane binding is con-
ferred by a myristoylated Cdk5 activator, p35. 
it is well documented that Cdk5 is deregulated 
by calpain-mediated cleavage of p35 to p25, 
a C-terminal Cdk5 activator fragment without 
the myristoylation site that translocates into 
the nucleus, leading to neuronal cell death. 
Membrane anchoring of active Cdk5 is a sur-
vival strategy for neurons.
The question of how Cdk5 causes neuronal 
cell death has been intensively investigated. 
One proposed hypothesis suggests that cell 
cycle is activated through Cdk5 phosphoryla-
tion of nuclear proteins. neurons reentering 
Cell Cycle News & Views
Cdk5-induced neuronal cell death: The activation of the conventional  
Rb-E2F G1 pathway in post-mitotic neurons
Comment on: Futatsugu A, et al. Cell Cycle 2012; 11:1603–10; PMID:22456337;  
http://dx.doi.org/10.4161/cc.20009
Shin-ichi Hisanaga* and Akiko Asada; Tokyo Metropolitan University; Hachioji, Japan; *Email: hisanaga-shinichi@tmu.ac.jp; http://dx.doi.org/10.4161/cc.20536
the cell cycle should accompany expression 
of cell cycle proteins. Considering expression 
of both Retinoblastoma (Rb) and e2Fs pro-
teins in neurons, the Rb-e2Fs pathway is the 
most likely Cdk5 target. e2Fs are transcription 
factors controlling G1 cell cycle progression, 
which is regulated by Rb. Hypophosphorylated 
Rb binds to and inhibits e2F activity, and 
when Rb is phosphorylated by Cdk4/6, it 
releases e2Fs to activate transcription activity. 
Although phosphorylation of Rb by Cdk5 is 
reported in vitro,3,4 it was not known whether 
this cascade functions in vivo. Futatsugi et al. 
have shown that Cdk5 is a major kinase that 
phosphorylates Rb at sites phosphorylated by 
Cdk4/6 using Cdk5−/− mouse brains.5 They also 
indicate that Cdk5-p25 stimulates e2F1 tran-
scription activity, and although they detect 
the presence of Cdk5 activity and phosphory-
lated Rb in the nucleus of neurons, the levels 
are insufficient for e2F activation in normal 
mouse brains. They propose that the pathway 
is mobilized when deregulated Cdk5 activity 
is increased in the nucleus. This is the first 
report that describes upregulation of e2F1 
transcription activity by Rb phosphorylation, 
the conventional G1 progression mechanism in 
Cdk5-dependent neuron cell death.
There are also two other mechanisms 
involved in Cdk5 regulation of e2Fs that are 
worth noting. Kim et al. showed that Cdk5-p25 
binds to and inhibits HDAC1 by phosphoryla-
tion, resulting in increased expression of cell 
cycle proteins including e2F1, which may fur-
ther stimulate G1 activity.
6 Zhang et al. reported 
that Cdk5-p35 binds e2F1 to inhibit dimer 
formation with DP1 in the nucleus of neurons 
in a kinase-independent manner.7 when cell 
cycle activity is initiated, Cdk5 is exported from 
the nucleus, resulting in e2Fs that create the 
transcriptionally active complex with DP1. it 
was recently reported that nuclear transport 
of Cdk5 is regulated by the p27 Cdk inhibitor8 
or Cdk5 activity itself.9 Therefore, there are at 
least three different molecular mechanisms 
involved in aberrant neuronal activation of 
e2Fs, which may be used differently according 
to death paradigms of neurons. Further, it is 
known that e2F1 can upregulate expression of 
proteins involved in apoptosis, although it is 
likely that e2F activation upregulates expres-
sion of cell cycle proteins as described above. 
Considering the potential therapeutics for 
Cdk5-induced neurodegenerative diseases, 
it is important to determine which death-
inducing signals activate which e2F activation 
pathways and which of cell cycle or apoptotic 
proteins the activated e2F upregulates.
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Meiosis is the differentiation pathway by which 
diploid cells produce haploid progeny for sexual 
reproduction. This specialized process involves 
one round of DnA replication, exchange of 
genetic material through recombination and 
haploidization achieved by two consecu-
tive nuclear divisions without an intervening 
s phase. Meiosis is a tightly regulated process, 
and the major steps in meiotic progression, 
including the duplication, recombination and 
segregation of the genome, are conserved 
among eukaryotes. The molecular mechanisms 
underlying these events have been the subject 
of extensive and fruitful investigations, in par-
ticular in two model systems, the budding yeast 
Saccharomyces cerevisiae and the fission yeast 
Schizosaccharomyces pombe. in a previous issue 
of Cell Cycle, Guerra-Moreno and colleagues 
presented a novel method for the synchronous 
induction of meiosis in fission yeast and used 
this approach to uncover new aspects of the 
meiosis-specific transcriptional program.
in fission yeast, meiosis involves a physi-
ological transition from vegetative growth, and 
initiation of the process requires inputs from a 
number of pathways, such as nutrient sensing 
and response to stress. Upon nitrogen depriva-
tion, haploid yeast cells mate to form diploids, 
which then undergo meiosis and produce four 
haploid spores (Fig. 1). A highly synchronous 
meiosis can be induced in S. pombe using a 
temperature-sensitive allele of the Pat1 kinase 
(pat1–114),1 a key negative regulator of the 
meiotic cycle. This system has been a powerful 
research tool, allowing for important discoveries 
in meiosis-specific RnA splicing, gene expres-
sion, recombination and chromosome segre-
gation. However, one of its major drawbacks is 
the requirement for a temperature shift, which 
has been shown to cause stress responses and 
changes in cellular physiology, notably in gene 
expression.2 Moreover, this precludes further 
dissection of the process through combination 
with the many temperature-sensitive muta-
tions that have been isolated in fission yeast, 
a significant resource for this model organism. 
To circumvent these issues, Guerra-Moreno et 
al. have developed a more optimal method 
for the synchronous induction of meiosis in S. 
pombe.3 Taking a chemical genetic strategy that 
has been used to regulate the activity of various 
families of kinases,4 they have engineered a 
mutation of Pat1 that renders it sensitive to spe-
cific inhibition by an ATP analog. inactivation of 
the kinase activity of this allele, pat1.L95G, after 
nitrogen deprivation resulted in synchronous 
entry into pre-meiotic s phase, progression 
through both meiotic divisions and formation 
of four haploid spores. The authors further 
validated this system by confirming the execu-
tion of characteristic splicing events that occur 
during meiosis.
in addition to establishing a promising 
new tool for the investigation of the mecha-
nisms of meiotic progression, this work has 
already yielded interesting results regarding 
its regulation. First, the authors investigated 
the transcriptional program of meiosis in fis-
sion yeast, in which hundreds of genes are 
expressed in successive waves.5 They verified 
that this pattern is generally preserved in their 
new system, with one surprising exception: 
although a number of transcripts associated 
with stress response were previously shown to 
be activated upon meiotic induction, Guerra-
Moreno and colleagues found a striking dif-
ference in the transcriptional profiles of these 
genes using the pat1.L95G allele, demonstrat-
ing that they are, in fact, only activated at later 
stages in the process. This indicates that the 
initial characterization of their expression pat-
tern was significantly affected by the tempera-
ture shift used in previous experiments and 
suggests that it will be critical to re-evaluate 
particular aspects of the meiotic program of 
transcription. second, the authors observed 
a delay in the timing of s phase entry in 
pat1.L95G compared with pat1–114, hinting at 
potential new roles for Pat1 independent of its 
kinase activity and identifying new directions 
for future research.
The results obtained using this induction 
system demonstrate its potential to contribute 
to our understanding of meiosis. The value and 
utility of such a method is further underscored 
by a second paper in this issue from Cipak et 
al., who have generated a different analog-
sensitive allele of pat1 that also achieves a 
highly synchronous meiosis.6 These comple-
mentary studies provide new insights into 
meiotic progression and highlight the power 
of this approach.
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Figure 1. Meiosis in fission yeast results in 
the production of four haploid spores from 
a diploid cell. The Pat1 kinase is a negative 
regulator of the meiotic process and its 
inactivation allows for meiotic entry. Box: 
DnA contents of nuclei are indicated by 1C 
(haploid), 2C (diploid) and 4C (diploid after 
DnA replication/pre-meiotic s phase).
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epigenetic changes have key roles in the 
initiation and progression of tumors. A pre-
dominant epigenetic modification in cancer 
is the silencing of tumor-suppressor genes 
by promoter DnA methylation at CpG islands. 
silencing of this group of genes, which sup-
press cell proliferation, inhibit metastases 
or promote cell death processes provides a 
strong positive selection to the tumor cells. 
interestingly, such epigenetic alterations 
occur not only at the different stages of tumor 
development, but also contribute to the 
acquisition of drug resistance, a major diffi-
culty in cancer treatment.1 in a recent issue of 
Cell Cycle, sidransky and colleagues describe 
an interesting example of specific gene silenc-
ing during the acquisition of drug resistance 
in malignant cells.2 The authors analyzed 
the gene promoter methylation profiles of 
non-small cell lung cancer (nsCLC) and head 
and neck squamous cell carcinoma (HnsCC) 
cell lines in comparison to their derivatives 
resistant to two anti-eGFR drugs, erlotinib 
(Tarceva) or cetuximab. The top ranked gene 
that was differentially methylated in resistant 
but not parental cells was identified as the 
tumor suppressor DAPk.2
DAPk is a calcium/calmodulin-regulated 
ser/Thr protein kinase that is implicated in 
various apoptotic, necrotic and autophagic 
cell death scenarios.3,4 Hypermethylation of 
the DAPk promoter has been documented in 
a large spectrum of human malignancies.4 The 
study by Ogawa et al. now describes DAPk as 
an essential factor for the successful treatment 
of nsCLC cell lines with anti-eGFR drugs and 
demonstrates the correlation between spe-
cific methylation of the DAPk promoter and 
acquisition of drug-resistance.2 DAPk protein 
expression was, accordingly, low in the drug 
resistant cells. Remarkably, re-introduction of 
DAPk into the resistant cells by stable trans-
fection restored the sensitivity of nsCLC cells 
to both erlotinib and cetuximab. Moreover, 
knockdown of DAPk protein expression in 
the parental, drug-sensitive, cells induced 
resistance to both drugs. This highlights the 
significance of DAPk in mediating cell death 
processes that are initiated by the anti-eGFR 
treatment, and that loss of DAPk leads to drug 
resistance and thus provides to these cells a 
significant growth advantage. Conversely, in 
the HnsCC cells, the resistance appeared to be 
DAPk-independent. This is most likely due to 
the fact that the DAPk promoter was already 
methylated to some extent in the parental 
HnsCC cells prior to attaining resistance. Thus, 
the specific genetic makeup of different malig-
nant cell populations at different stages has a 
dramatic influence on the success of different 
therapeutic interventions.
The multiple functions of DAPk in sensitiz-
ing cells to apoptotic and necrotic responses, 
in mediating autophagy and in blocking 
metastasis contribute to its tumor-suppres-
sive properties. it is therefore not surprising 
that a modification that eliminates expression 
of this gene will be positively selected during 
tumorigenesis. The data presented by Ogawa 
et al. suggest that from the various stochastic 
epigenetic changes that occurred through 
the course of the drug treatment, cells that 
acquired silencing of the DAPk gene survived 
and created a subpopulation of resistant cells 
that prevailed. One of the future challenges 
will be to discover the molecular mechanisms 
that link DAPk to the cytotoxicity induced 
by the anti-eGPR drug. interestingly, eGFR 
inhibitors have been recently documented to 
elevate reactive oxygen species in cells and to 
induce cytotoxicity through oxidative stress.5 
we have previously reported that DAPk is a 
major regulator of the cellular response to 
oxidative stress, acting through activation of 
protein kinase D and JnK to mediate both pro-
grammed necrosis as well as autophagy.6,7 it is 
therefore plausible that the resistance to cyto-
toxicity of the anti-eGFR agents demonstrated 
here is due to loss of this important redox-sen-
sitive, death-promoting mechanism, which is 
mediated by DAPk. Previous reports also con-
nected the loss of DAPk expression with resis-
tance to other chemotherapeutic agents used 
to treat gastric cancer.8 Like the anti-eGFR 
therapy, a significant part of chemotherapy-
induced cytotoxicity is via induction of oxida-
tive stress9 and may, therefore, be dependent 
on DAPk. Finally, it should be stressed that 
further studies are required to clinically con-
firm the cell culture findings reported in this 
work by measuring the methylation status 
of DAPk in tumor specimens obtained from 
patients who acquired drug resistance along 
the course of treatment. The clinical data will 
indicate whether the assessment of DAPk 
methylation may be an important factor in 
choosing a specific course of therapy and pre-
dicting drug resistance.
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endoplasmic reticulum (eR) stress can affect 
the function of both oncogenes and tumor 
suppressor genes, conducting to altered sig-
naling pathways regulating cell proliferation 
and homeostasis.1 However, the mechanisms 
by which eR stress affects the function of onco-
genes and tumor suppressor genes remain 
elusive. in a recent issue of Cell Cycle, Macaluso 
et al.2 investigated the contribution of the 
chromatin insulator CCCTC-binding factor 
(CTCF) and of brother of the regulator of the 
imprinted site (BORis) to the role of the large 
T antigen (T-Ag) in maintaining chronic eR 
stress. T-Ag is known to inactivate both p53 
and pRB family proteins (pRB1/p105, pRB2/
p130 and p107).3 As such, the authors hypoth-
esized that BORis, CTCF and pRB2/p130 may 
have altered behaviors in order to maintain 
chronic eR stress in T-Ag-positive cancer cells.
CTCF can be considered as a potential 
tumor-suppressor factor, whereas BORis 
(CTCFL) has to be considered as a new onco-
gene.4 Current literature suggests that CTCF 
and BORis, both exhibiting an 11 zinc finger 
have DnA binding competition activities and 
thus elicit opposite changes in gene expres-
sion. CTCF is an evolutionarily conserved and 
ubiquitously expressed protein that binds 
to approximately 20,000 sites in the human 
genome.4 ectopic expression of CTCF in var-
ious normal and tumoral human cell lines 
inhibits cell division and clonogenicity. BORis 
is not found or is eventually found at low 
levels in normal cells or tissues. BORis gene 
expression is predominantly epigenetically 
controlled by DnA methylation, considering 
that its activation requires the demethylation 
of its promoter, a mechanism frequently occur-
ring in cancers due to global genome-wide 
hypomethylation.5
in the paper by Macaluso et al.,2 the authors 
tried to demonstrate that the T-Ag, conferring 
oncogenic properties to the Polyomavirus, 
may contribute to maintain altered signal-
ing pathways triggered by Rb2/p130, BORis 
and CTCF. This study performed on medul-
loblastoma cells, nicely brings further insights 
to their previous work, in which they could 
show that CTCF and BORis directly bind the 
Rb2/p130 promoter and thus have a tran-
scriptional regulatory effect on this gene.6 
Presently, they could demonstrate that CTCF 
binds to the pRB2/p130 promoter only in 
T-Ag-negative cells, suggesting that the pres-
ence of the T-Ag alters the binding of CTCF.2 
However, it is not yet known whether, this 
modification selectively occurs for the pRB2/
p130 promoter or only for some promoters, 
or whether it is a whole genome-wide modi-
fication, which would be interesting to inves-
tigate. Furthermore, they found that pRB2/
p130 interacts with either CTCF or with BORis, 
since they could determine that pRB2/p130 
co-immunoprecipitates and co-localizes with 
these proteins (Fig. 1). surprisingly, it was 
observed that these complexes exclusively 
occur in the eR of medulloblastoma tissues in 
contrast to medulloblastoma cell lines, where 
they occur in the nucleus as well in the cyto-
plasm. eR stress can be induced by hypoxia or 
low glucose levels. Macaluso et al. observed,2 
in T-Ag-negative cells, that glucose deprivation 
induced perinuclear aggregates of pRB2/p130 
with BORis and CTCF an event that is already 
occurring in T-Ag-positive cells under normal 
glucose conditions (Fig. 1). Additionally, eR 
stress seems to discard the pro-active form at 
the expense of the active form of caspase 12 
(Fig. 1).2
The most encouraging observation made 
by Macaluso et al.,2 is that T-Ag appears to 
prepare cancer cells for continued cell death 
dictated by a microenvironment poor in nutri-
ents, i.e., low glucose levels, via inducing peri-
nuclear aggregates of pRB2/p130 with CTCF 
and BORis. The significance of the accumula-
tion of these perinuclear aggregates is unclear, 
Figure 1. sub-cellular localization of pRb2/p130, CTCF, BORis in T-Ag positive cells (BsB7) and T-Ag 
negative cells (Bs1a) in normal conditions and eR stress conditions (glucose deprivation). separate 
icons of the proteins means diffuse localization whereas pooled icons mean aggregated proteins 
located at perinuclear sites. eR; endoplasmic reticulum. nu; nucleus.
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ideally, targeted cancer therapy is directed 
against tumor cells while sparing normal cells. 
But in reality, most of the chemotherapeu-
tic drugs currently used in the clinics only 
partially confer this selectivity. As a result, all 
rapidly dividing tissues are affected by chemo-
therapy, resulting in severe side effects, such as 
immunosuppression, bleeding, diarrhea and 
hair loss.
Being the product of the most frequently 
mutated gene in cancer, the tumor suppressor 
p53 represents a highly attractive target for 
therapeutic approaches aiming at the selec-
tive killing of tumor cells. some strategies for 
p53-based therapy rely on the reconstitution 
of wild-type p53 in tumor cells, e.g., by adeno-
viral gene delivery. More recently, the concept 
of converting mutant p53 into a killer of tumor 
cells was proposed.1 Pharmacological reac-
tivation of mutant p53 reportedly results in 
conformational changes, restoring DnA bind-
ing ability and transcriptional activity and, 
thus, the capability to induce cell cycle arrest, 
senescence or apoptosis.2 However, the use of 
these drugs is still a challenge due to the het-
erogeneity of p53 mutations in tumors, each 
differing structurally and functionally.
in the past decade, cyclotherapy has 
emerged as a novel strategy where an inital 
treatment induces reversible growth arrest 
in normal cells, shielding them from classical 
chemotherapeutic treatment that only affects 
“cycling” cancer cells.3,4
p53-based cyclotherapy depends on the 
activation of wild-type p53 in normal cells. 
This concept seems counterintuitive at first 
glance, since p53 is mostly known as an 
inducer of cell death—obviously an undesir-
able effect with regard to normal cells of 
patients. However, moderately activating p53 
rather results in cell cycle arrest than apop-
tosis. The induction of p53 may also protect 
cells by induction of repair genes or by alter-
ing the proapoptotic DnA damage response.5 
in this context, p53 serves as a discriminator 
between normal cells, with wild-type p53 and 
tumor cells lacking functional p53. Patients 
with tumors bearing p53 mutations could 
benefit from this combinatorial approach: 
initial treatment with a p53 activator spares 
healthy tissue from cytotoxic effects associ-
ated with classical chemotherapy, and only 
tumor cells harboring p53 mutations are 
eliminated.
i.e., whether it is due to redistribution or it 
comes from an increase in the protein synthe-
sis, the latter being a more plausible hypoth-
esis. indeed, the eR is the major site for folding 
and trafficking. when the eR is stressed by 
unfolded proteins, it elicits a classic adaptative 
response known as unfolded protein response 
(UPR).7 Aggresome-like induced structures 
(ALis) are known to result from transient 
aggregation of ubiquitinated proteins in eR 
stress response.8 A crosstalk between UPR and 
ALis was recently reported.8 Obtaining infor-
mation as to whether pRb2/p130, BORis and 
CTCF are affected by unfolding, ubiquitnation 
or truncation will probably shed light on how 
the subcellular localization of CFTC, BORis and 
pRB2/p130 is tuned to orchestrate intercon-
nected p53-independent signaling pathways 
leading to cancer cell death in Polyomavirus-
infected cells. Furthermore, it will unravel how 
cancer cells can be selected for survival and 
thus acquire resistance to cell death signaling.
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Figure 1. p53-mediated chemoprotection. 
some chemotherapeutics are largely 
restricted in their efficacy to specific 
phases in the cell cycle. nucleoside analogs 
(gemcitabine, cytarabine) work in s-phase, 
whereas taxanes and vinca alcaloids act on 
mitotic cells. Moderate activation of p53 
arrests cells in G1 or G2, protecting p53-
proficient cells (but not p53 mutant tumor 
cells) against these drugs.
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Previous studies indicate that pretreat-
ment with the p53 activator nutlin-3 protected 
human fibroblasts from taxanes6 and human 
immortalized keratinocytes from nucleoside 
analogs7 as well as from cell death induced by 
Uv irradiation.5
in a previous issue of Cell Cycle, Leeuwen 
and colleagues extended this approach, show-
ing that a variety of p53-activating strategies 
(actinomycin D, nutlin-3, tenovin-6, lepto-
mycin  B) led to reversible cell cycle arrest 
in human fibroblasts, protecting them from 
drugs that are active in s phase (gemcitabine 
and cytarabine) and M phase (vinblastine, 
vinorelbine).8 Thus, arresting normal cells may 
provide a promising strategy of chemoprotec-
tion, enabling the use of higher doses of che-
motherapeutics in patients.
However, fibroblasts are not the cells 
harmed by the side effects of chemotherapy 
in first place. Chemotherapy mostly damages 
highly proliferating tissues like bone marrow, 
epithelia of the digestive tract and hair follicles. 
Further investigations are required to evalu-
ate if cells from these tissues are protected by 
p53-mediated cyclotherapy.
The study by Leeuwen et al. also indicates 
that sometimes p53-mutant and p53-null cell 
lines were protected by cyclotherapy, depend-
ing on the drug used for pre-treatment, poten-
tially compromising the therapeutic efficacy.8 
in contrast, this effect was not observed for the 
p53-selective drug, nutlin-3.
As nutlin-3 interacts with MDM2, a nega-
tive regulator of p53, its effects are highly 
p53-dependent.9 The major disadvantage 
of nutlin-3 is that it has not been clinically 
approved so far. For instance, p53-induced 
myelodepression may limit its use. Phase  i 
clinical trials are currently ongoing using 
the related compound RG7112 as a mono-
therapy for the treatment of hematologic 
neoplasms (nCT00623870) and solid tumors 
(nCT00559533).
Critical issues remain to be addressed: is 
p53-based cyclotherapy clinically applicable? 
Are there dose-limiting effects of combinatorial 
treatments? what impact has p53 preactivation 
on the side effects of chemotherapy in non-pro-
liferating cells, e.g. neurons or cardiomyocytes?
Beyond understanding the underlying 
mechanisms of p53 as a chemoprotector, the 
feasibility of the combinatorial treatment 
needs to be verified in preclinical studies and 
clinical trials. This would finally exploit the 
most frequent genetic alteration in cancer for 
a selective therapy.
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